Reuters reveals Tens of millions of J&J COVID-19 shots sit at Baltimore factory

Reuters broke the news that an estimated 30 million to 50 million doses of Johnson & Johnson’s COVID-19 vaccine made earlier this year sit idle in Emergent BioSolutions Inc’s plant in Baltimore, awaiting a green light from U.S. regulators to ship. A source said Emergent is waiting for the U.S. Food and Drug Administration to approve release of those doses. Emergent shares opened nearly 1% higher following the Reuters report.